Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;24(5):276-82.
doi: 10.1097/FPC.0000000000000040.

PharmGKB summary: abacavir pathway

Julia M Barbarino  1 , Deanna L Kroetz, Russ B Altman, Teri E Klein
Affiliations

PharmGKB summary: abacavir pathway

Julia M Barbarino et al. Pharmacogenet Genomics. 2014 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of abacavir pharmacokinetics and pharmacodynamics. The potential mechanism of an abacavir hypersensitivity reaction is also shown and is drawn using dashed lines as it is not currently well established. A fully interactive version is available online at http://www.pharmgkb.org/pathway/PA166104634.
Fig. 2
Fig. 2
Structures for abacavir, CBV-TP, and deoxyguanosine triphosphate (dGTP). Note the similarities in structure between CBV-TP and dGTP, excluding the absence of the critical free 3’-OH group on the deoxyribose sugar ring in CBV-TP. This absence prevents the addition of any additional nucleotides and blocks further viral DNA synthesis. CBV-TP, (–)-carbovir 5’-triphosphate.
See this image and copyright information in PMC

References

    1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012. 308:387–402. - PubMed
    1. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351–371. - PubMed
    1. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91:734–738. - PMC - PubMed
    1. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732. - PubMed
    1. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999;13:1419–1420. - PubMed

Publication types